Cell Therapy News

The FDA has included tocilizumab among its list of drugs currently in shortage.

The combination of tumor-infiltrating lymphocytes and nivolumab induced tumor regression among more than two-thirds of patients with stage IV non-small cell lung cancer, according to results of a phase 1 study published in Nature Medicine.

Few scientific advances have generated the optimism and enthusiasm that surround CRISPR.

A randomized phase 3 trial that evaluated tisagenlecleucel as second-line treatment of relapsed or refractory aggressive B-cell non-Hodgkin lymphoma failed to meet its primary endpoint of improved EFS, according to the agent’s manufacturer.

Most patients who received one of two investigational natural killer cell therapy regimens for relapsed or refractory B-cell lymphoma achieved complete response, according to topline data released by the agents’ manufacturer.

A lower dose of cyclophosphamide during preconditioning prior to tumor-infiltrating lymphocyte infusion appeared comparably effective but less toxic than a higher dose, according to results published in Journal for ImmunoTherapy of Cancer.

The FDA cleared an investigational new drug application for KITE-363, a chimeric antigen receptor T-cell therapy designed to treat adults with relapsed or refractory large B-cell lymphoma.

The FDA granted orphan drug designation to ALLO-715 for the treatment of advanced multiple myeloma, according to the agent’s manufacturer.

A trial designed to evaluate maveropepimut-S for women with advanced recurrent ovarian cancer demonstrated encouraging activity, according to the agent’s manufacturer.

The FDA placed a clinical hold on a phase 3 study designed to evaluate elivaldogene autotemcel, an investigational gene therapy, for the treatment of younger patients with cerebral adrenoleukodystrophy.